Friday, 21 February 2025
  
Login

Australia's most trusted
source of pharma news

Friday, 21 February 2025
Ascott/Vivacity
Ascott/Vivacity
Pharma sells for 66% below peak

This high-profile ASX-listed company has unveiled a deal that will see a US pharma pay $672 million to buy it. But the price is a fraction of the $2 billion it was once worth.

Upheaval heading to industry
ICYMI: The most popular stories this week with forecast changes to organisational structures topping the list
TODAY Your Week in 5 Minutes
15 drugs land on TGA review list
Find out whose applications the regulator has accepted to kick off 2025 with seven innovative medicines on the cards
TODAY
emotivate
emotivate
PBS hopefuls surge for March
After a quiet start to the year for reimbursements, listings could heat up as the next federal election nears
20 February
Analysts tip next top sellers
Rankings for pharma's leading investigational drug candidates. See the next wave of biggest earners
19 February
Big changes coming to pharma
Organisational structures and leadership set to significantly change the way industry does business
18 February
Trial astounds in blood cancer
Over half of patients in Aussie CAR T trial showed complete response after failing multiple treatments
18 February
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (25)

Clinical & Medical, R&D (13)

Regulatory, Pharmacovigilance & QA (2)

Executive Roles (1)

Other (11)

CSL raids banking sector for exec
Company puts another piece in place in its new Corporate Affairs team, appointing a new Director of Corporate Comms
TODAY
TGA approves first-in-class drug
Perfect timing: Priority review sees the tick come a month before this treatment is considered by the PBAC
TODAY
Bastas gifts $7.5M for better leaders
Billionaire establishes the Bastas Academy for Health Leadership to address critical leadership and workforce challenges
20 February
Company fills two new GM roles
General Manager of Medical Relations and General Manager of Medical Sales to bolster prescriber education and improve outcomes
20 February
Leader scores spot in star line-up
Selected to speak alongside a former PM, Foreign Minister and Australia's most highly decorated Olympic gold medalist
20 February
GBMA calls for biosim discount
Peak body wants the Federal Government to promote biosimilar use over originator brands with a cheaper copay
20 February
GPs urge schooling in rare disease
Lack of confidence in diagnosing rare diseases presents an opportunity for pharma to fill the gap with education
19 February
Billions lost in 2024 trial flops
Failures in late-stage trials saw pharmas write off billions in assets and lose billions in market cap
19 February
Pfizer takes GP education 'to heart'
Joins forces with Heart of Australia to expand its GP Education Program and boost healthcare in rural and remote areas
19 February
Pain experts slam Govt yet again
Launch of 11-point plan to resolve med supply crisis as those responsible "seem stuck for answers"
19 February
$50M cash influx to disrupt market
Work to begin in July 2025 following the largest single philanthropic investment in vision science in Australia
18 February
Novartis signs Aussie research pact
Company enters MoU for a long-term research partnership aimed a delivering real-world impact for patients
18 February
Tackling industry's digital absence
Calling pharma marketers: new workshop focuses on using digital channels to meet patients where they are online
18 February
Expensive drugs fail to earn big
Despite the high ticket price, cell and gene therapies don't add much to the bottom line
17 February
Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.